Härtig, Florian
Birschmann, Ingvild
Peter, Andreas
Hörber, Sebastian
Ebner, Matthias
Sonnleitner, Matthias
Spencer, Charlotte
Bombach, Paula
Stefanou, Maria-Ioanna
Kuhn, Joachim
Mengel, Annerose
Ziemann, Ulf
Poli, Sven
Article History
First Online: 20 May 2020
Compliance with ethical standards
:
: F. Härtig and M. Ebner received reimbursement for congress traveling from Bayer. I. Birschmann received speaker’s honoraria from Aspen Germany, Bristol-Myers Squibb/Pfizer, Siemens Healthcare, and CSL Behring, and reimbursement for congress traveling from aspen and Bristol-Myers Squibb, and performed contract research for Siemens Healthcare. Ingvild Birschmann is a member of the advisory board of LFB biomedicaments. U. Ziemann received grants from German Research Foundation, German Federal Ministry of Education and Research, European Research Council, Bristol-Myers Squibb, Janssen Pharmaceuticals, Servier, and Biogen Idec, and consulting honoraria from Pfizer, Bayer Vital, and CorTec (all outside of the present work). S. Poli received speaker’s/consulting honoraria from Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, and Werfen, reimbursement for congress traveling from Bayer, and Boehringer-Ingelheim, and research support from Bristol-Myers Squibb/Pfizer, Boehringer-Ingelheim, Daiichi Sankyo, and Helena Laboratories (all outside of the present work). The other authors (A. Peter, S. Hörber, M. Sonnleitner, C. Spencer, P. Bombach, M.-I. Stefanou, J. Kuhn, and A. Mengel) report no conflicts of interest.